Trials / Completed
CompletedNCT01245374
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
Assessment of the Ease of Use of Norditropin NordiFlex® Relative to the One of the Device Previously Used by Patients or Parents
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
This study is conducted in Europe. The aim of this study is to compare the easiness of use of Norditropin NordiFlex® device to the device previously used by patients or parents.
Conditions
- Growth Hormone Disorder
- Growth Hormone Deficiency in Children
- Foetal Growth Problem
- Small for Gestational Age
- Genetic Disorder
- Turner Syndrome
- Chronic Kidney Disease
- Chronic Renal Insufficiency
- Delivery Systems
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Norditropin NordiFlex® | Daily administration by a subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-04-01
- Completion
- 2011-04-01
- First posted
- 2010-11-22
- Last updated
- 2017-02-27
- Results posted
- 2012-06-25
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01245374. Inclusion in this directory is not an endorsement.